Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - kopsuarteri hüpertensiooni (pah) ravi, et parandada who funktsionaalse iii klassi patsientide treenimisvõimet ja sümptomeid. efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. mõningaid parandusi on ka näidanud patsientidel pah who funktsionaalse klassi ii. tracleer on ka märgitud arvu vähendada uue digitaalse haavandid patsientidel süsteemne multiplex ja pidev digitaalne haavand haigus.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ambrisentaan - hüpertensioon, kopsuvähk - antihypertensives, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkootikumid luuhaiguste raviks - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Estonia - Tiếng Estonia - Ravimiamet

krka d.d. novo mesto - simvastatiin - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 60tk

Estonia - Tiếng Estonia - Ravimiamet

accord healthcare b.v. - simvastatiin - õhukese polümeerikattega tablett - 20mg 56tk; 20mg 28tk; 20mg 30tk; 20mg 98tk; 20mg 50tk; 20mg 500tk; 20mg 84tk; 20mg 10tk; 20mg 1000tk

Estonia - Tiếng Estonia - Ravimiamet

accord healthcare b.v. - simvastatiin - õhukese polümeerikattega tablett - 40mg 100tk; 40mg 10tk; 40mg 500tk; 40mg 14tk; 40mg 56tk; 40mg 1000tk; 40mg 90tk; 40mg 98tk; 40mg 250tk

Estonia - Tiếng Estonia - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 84tk; 20mg 28tk; 20mg 90tk; 20mg 30tk; 20mg 100tk; 20mg 10tk; 20mg 98tk; 20mg 56tk

Estonia - Tiếng Estonia - Ravimiamet

merck sharp & dohme oÜ - simvastatiin - õhukese polümeerikattega tablett - 10mg 28tk

Estonia - Tiếng Estonia - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 90tk; 10mg 60tk; 10mg 84tk; 10mg 14tk; 10mg 20tk; 10mg 98tk; 10mg 56tk; 10mg 10tk

Estonia - Tiếng Estonia - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 80mg 30tk; 80mg 98tk; 80mg 50tk; 80mg 56tk; 80mg 28tk; 80mg 84tk; 80mg 100tk; 80mg 10tk